Prognostic value of glycated hemoglobin in colorectal cancer

Table 1 Clinical characteristics of colorectal cancer patients - comparison between patients with or without impaired glucose tolerance or type 2 diabetes

	IGT or T2D		P value
	NO (n = 173)	YES (n = 51)
Age (yr)
mean ± SD (range)	64 ± 10 (30-83)	66 ± 8 (54-80)	0.127
Sex, n (%)
Males	103 (60)	30 (59)
Females	70 (40)	21 (41)	0.927
Body mass index
mean ± SD (range)	25.4 ± 4.1 (17.2-38.4)	26.5 ± 4.2 (17.2-38.4)	0.105
HOMA index
Median (IQR)	2.80 (1.83-4.79)	6.48 (3.95-10.26)	< 0.0001
HbA1c
mean ± SD (range)	5.72 ± 0.36 (4.30-7.10)	6.87 ± 1.25 (5.30-13.0)	< 0.0001
Blood lipids (mg/dL)
Total cholesterol	187 ± 42	189 ± 48	0.782
HDL cholesterol	47 ± 12	44 ± 13	0.284
LDL cholesterol	113 ± 38	117 ± 41	0.618
Triglycerides	136 ± 69	138 ± 52	0.838
Site, n (%)
Colon	126 (73)	33 (65)
Rectum	47 (27)	18 (35)	0.293
Histological diagnosis, n (%)
Adenocarcinoma
Mucinous	30 (17)	10 (20)
Non-mucinous	140 (81)	40 (78)
Others1	3 (2)	1 (2)	0.933
ECOG performance status, n (%)
0	150 (91)	40 (82)
1	14 (8)	9 (18)
2	1 (1)	0 (0)	0.129
Stage, n (%)
I	3 (2)	1 (2)
IIA	26 (15)	6 (12)
IIB	4 (2)	1 (2)
IIIA	3 (2)	1 (2)
IIIB	37 (21)	8 (15)
IIIC	9 (5)	5 (10)
Metastatic	91 (53)	29 (57)	0.875

¹Including 3 non diabetic patients with undifferentiated, squamous and mixed neuroendocrine cancers (one each) and one type 2 diabetes (T2D) patient with undifferentiated cancer. CRC: Colorectal cancer; IGT: Impaired glucose tolerance.